Literature DB >> 22883219

18F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma.

Frederic Di Fiore1, Valérie Blondin, Anne Hitzel, Agathe Edet-Sanson, Ahmed Benyoucef, Emmanuel Huet, Pierre Vera, Pierre Michel.   

Abstract

BACKGROUND: The purpose of the study was to investigate the value of 18F-fluorodeoxyglucose-positron emission tomography performed after definitive chemoradiotherapy in patients with locally advanced oesophageal carcinoma.
METHODS: Forty consecutive patients underwent 18F-fluorodeoxyglucose-positron emission tomography at baseline and after chemoradiotherapy completion. Assessment of the clinical complete response to chemoradiotherapy included oesophagoscopy plus biopsies and computed tomography scan. Cox regression analysis was used to develop the univariate and multivariate models describing the association of the independent variables with survival and local control.
RESULTS: A clinical complete response and 18F-fluorodeoxyglucose-positron emission tomography response were present in 29 patients (72.5%) and 13 patients (32.5%), respectively. A combined response was observed in 11 patients (27.5%). During follow-up, a local failure was detected in 27.2% of patients with 18F-fluorodeoxyglucose-positron emission tomography response versus 33.3% in non-responders (p=.9). In multivariate analysis, clinical complete response (HR 5.77, p=.009) and 18F-fluorodeoxyglucose-positron emission tomography response (HR 6.27, p=.031) were identified as independent prognostic factors of overall survival.
CONCLUSION: In patients treated for an esophageal cancer, the present study suggested that 18F-fluorodeoxyglucose-positron emission tomography after chemoradiotherapy completion was an independent prognostic factor of overall survival without significant impact on local recurrence prediction.
Copyright © 2012 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22883219     DOI: 10.1016/j.dld.2012.04.017

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  5 in total

1.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Authors:  Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-14       Impact factor: 9.236

2.  The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).

Authors:  Odré Palie; Pierre Michel; Jean-François Ménard; Caroline Rousseau; Emmanuel Rio; Boumédiene Bridji; Ahmed Benyoucef; Marc-Etienne Meyer; Khadija Jalali; Stéphane Bardet; Che Mabubu M'vondo; Pierre Olivier; Guillaume Faure; Emmanuel Itti; Christian Diana; Claire Houzard; Françoise Mornex; Frederic Di Fiore; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

3.  Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Authors:  Charles Lemarignier; Frédéric Di Fiore; Charline Marre; Sébastien Hapdey; Romain Modzelewski; Pierrick Gouel; Pierre Michel; Bernard Dubray; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-19       Impact factor: 9.236

4.  Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.

Authors:  Min Fang; Tao Song; Xiaodong Liang; Shiliang Lv; Jianbo Li; Hong'en Xu; Limin Luo; Yongshi Jia
Journal:  Oncotarget       Date:  2017-06-06

Review 5.  The application of functional imaging techniques to personalise chemoradiotherapy in upper gastrointestinal malignancies.

Authors:  J M Wilson; M Partridge; M Hawkins
Journal:  Clin Oncol (R Coll Radiol)       Date:  2014-07-04       Impact factor: 4.126

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.